Our products

Transforming medical diagnosis with the power of Phivea®

Phivea® is a comprehensive decision support software for healthcare professionals, which allows for accurate and timely diagnosis of genetic disorders and real-time prediction of clinical interventions.

Phivea® employs advanced Artificial Intelligence and customized Deep Learning architectures at all levels of the learning process, from feature extraction to assessment and follow-up care.

Patient data are secured by blockchain technology. To ensure maximal security, Phivea® uses two types of security, cryptography and hashing, thus producing a structure of data with inherent security qualities.

As a result, Phivea® produces encrypted data in a more sensitive and secured manner within a shorter period of time.

Phivea® is automated, transcending the need for bioinformatician’s intervention, reducing the experimental errors and costs. This improves accessibility and has a potential to revolutionize genetic analysis without any change to current health care protocols.

How it works

Phivea® can be operated with any third-party sequencing technology to classify genetic disorders and perform quality control on DNA reads.

The software uses state-of-the-art Machine Learning algorithms to create dataflow pipelines for classification or prediction, based on recent research in genome sequence analysis that fulfils rigorous quality criteria.

Different Deep Learning and customized multi-level decision architecture are employed for every step in the learning process, from feature extraction to pipeline architecture.

For improved predictive performance, efficiency and clarity of datasets, Phivea® combines pre-trained multiple base and conceptual models that can be fine-tuned to detect genetic disorders. The multi model fusion strategy built on top of the individual models combines their outcome into a singular final medical interpretation.

  • Phivea® enables simultaneous analysis of up to 384 samples.
  • Diagnostic parameters showed >99% Sensitivity & >99% Specificity
    for patients (97% & 99.1% respectively for individual replicates).
    Karyotype is the current standard with 63% sensitivity & +99% specificity.
  • Limit of detection (LoD): Phivea® Platform can detect mosaicism
    in a Klinefelter male down to 25.3%.
    LoD was 27.9% 
    when Klinefelter sample was mixed with a female 
  • Phivea® aligns a sequence in 1.1 milliseconds,
    which is more than 50 times faster than the Smith–Waterman algorithm.
  • In terms of computational efficiency, Phivea® is 10 times faster than the guppy barcoder.


Intended Purpose

Available in:


Instructions for Use

Available in:




Licensing and Accreditation

Declaration of Conformity in:


For technical support and other inquiries, contact [email protected]